HTA

What's powering Novartis's Q2 sales rebound? The pharma leader has posted renewed growth, fueled by strong momentum from its latest product launches across key portfolios. These results highlight the company's strategic focus on innovation and pipeline delivery. Read the full breakdown on Syenza. #SyenzaNews #pharmaceuticals #biotech #innovation #MarketAccess

How is NICE expanding treatment options for HFpEF patients? The UK’s National Institute for Health and Care Excellence has approved finerenone, giving clinicians a new evidence-based therapy to improve outcomes in heart failure with preserved ejection fraction. This milestone broadens the therapeutic landscape and reinforces the value of targeted drug development. Read the full analysis. #SyenzaNews #pharmaceuticals #HealthcareInnovation #innovation #MarketAccess

💊 What does South Africa’s approval of generic semaglutide mean for patients and payers? Following patent expiration, the green light for generic versions promises lower costs and wider access to this key treatment for type 2 diabetes and weight management. Explore how this decision could reshape market access and affordability across emerging economies. #SyenzaNews #pharmaceuticals #drugdevelopment #MarketAccess #costeffectiveness

How is expanding tablet manufacturing capacity reshaping pharma supply resilience? Recent capacity boosts are helping manufacturers meet rising demand while reducing disruption risks across global medication flows. This move strengthens continuity for patients and providers alike. Discover the strategic details behind the expansion. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #strategicplanning

What opportunities do EIT Health’s 2027 grants unlock for Europe’s health innovators? New provisions prioritize cross-border collaboration, sustainability, and digital solutions, with major implications for startups, researchers, and health systems seeking funding. Explore how these changes could shape your next project. #SyenzaNews #HealthcareInnovation #HealthTech #innovation

🧐 Why does the US spend 17.5% of GDP on health yet leave coverage so unequal? Adverse selection and asymmetric information distort markets. The “three-legged stool” of reforms covered millions, but durable cost control remains elusive. Read the full analysis → #HealthEconomics #USHealthcare #PolicySolutions #SyenzaNews

📊 How is Portugal turning hospital data into powerful population health insights? A new data platform is enabling deeper analysis of health trends, outcomes, and resource use across patient populations. Explore how this approach is advancing data-driven decision-making in healthcare. #SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #datascience

Could earlier surveillance after TAVR unlock better outcomes at lower cost? 💡📈 A new analysis finds that proactive early‑post‑TAVR surveillance has the potential to be cost‑effective — and in many modeled scenarios, economically dominant — by improving patient outcomes while reducing downstream costs. The piece highlights key assumptions, sensitivity analyses, and implications for clinicians, payers, and policymakers. Read the full article to understand the evidence and what it means for adopting early surveillance strategies. #SyenzaNews #HealthEconomics #HealthTechnology #costeffectiveness #MarketAccess

Could a strategic stake reshape pharma access across Africa? 🌍 Natco Pharma and Adcock Ingram’s move signals a concerted push into African markets — combining manufacturing scale and regional distribution to expand access to essential medicines and capture fast-growing demand. This partnership underlines key market-access, regulatory and supply-chain shifts investors and healthcare leaders should monitor. 💊 Read the full piece to understand the deal terms, strategic rationale and implications for regional healthcare growth. #SyenzaNews #pharmaceuticals #globalhealth #MarketAccess #innovation

Can Portugal's generic drug industry weather the storm of growing global instability? 🌍 This analysis shows how supply‑chain shocks, API dependencies and rising costs are pushing Portuguese manufacturers and policymakers toward onshoring, supplier diversification and greener production to safeguard access and long‑term sustainability. ♻️ Read the full article for practical policy recommendations and industry strategies shaping a more resilient generics sector. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #healthcarepolicy

Could smarter procurement be the catalyst for rebuilding South Africa’s healthcare infrastructure? 🏥 This article explores how targeted procurement reforms — from centralized e-procurement and value-based purchasing to supplier development and public–private partnerships — are unlocking investment, strengthening supply chains, and supporting local manufacturing. Those shifts can lower costs, improve transparency, and accelerate delivery of critical facilities and services. Read the full piece to discover practical recommendations and policy levers for policymakers, providers, and suppliers. #SyenzaNews #healthcare #HealthcareInnovation #resourceallocation #healthcarepolicy

Could conditional adoption pathways unlock faster access to better endometriosis diagnostics? 🔍 This piece outlines pragmatic routes—conditional reimbursement, coverage-with-evidence development, and staged rollouts—that balance earlier patient access with real-world evidence generation. It also highlights stakeholder alignment, outcome metrics, and market-access considerations developers and payers need to navigate. Read the full article for actionable frameworks and a checklist to responsibly bring diagnostic innovations to market. #SyenzaNews #HealthTech #clinicaltrials #MarketAccess #healthcarepolicy